Valeo Pharma Obtains Public Reimbursement For Asthma Drugs In Quebec and Nova Scotia, Another Step Closer to 2025 Revenue Target of $160M

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market. This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies. Q3 Highlights: Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over the prior quarter. Record gross margin of $2.2 million, up 1602% over Q3 2020 and 204% over the prior quarter. Record 9 months revenues at $10.2 million, up 94% Clearly, Valeo Pharma is firing on all cylinders. This is evident by the company’s recent announcement that they Obtained Public Reimbursement For Enerzair® Breezhaler® And Atectura® Breezhaler® In Quebec And Nova Scotia. Public reimbursement now includes Alberta, Quebec, and Nova Scotia, representing approximately 37% of the Canadian population. More than 90% of private insurance coverage across Canada Frederic Fasano, Valeo's President, and Chief Operating Officer commented, "We are pleased to be reporting today the addition of Quebec and Nova Scotia to join Alberta on the list of provincial public coverage secured for both asthma medications. Public Reimbursement access makes a meaningful impact for asthma patients left with no coverage so far and also simplifies health care providers' procedures to provide access to both medications to their patients. Enerzair and Atectura are innovative asthma therapies that are helping make asthma control a more attainable goal for Canadian asthma patients". But wait, there’s more… The company just Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec. Now sit back, relax and watch this powerful interview with Valeo Pharma.